A £50m contract, a £330m NHS review, and a pre action letter now ask the same question: can British institutions break a single vendor US tech dependency on process grounds?
The Metropolitan Police wanted Palantir's software to automate intelligence analysis across criminal investigations. Sadiq Khan refused to sign off on the £50m contract in late May, citing a breach of UK procurement rules and the fact that Palantir had been the only bidder. Palantir's lawyers have now told the Mayor's Office for Policing and Crime they intend to challenge the block in court, according to the Guardian. Khan's office confirmed receipt of the pre-action letter. The dispute, still at the pre-action stage, is the first real legal test of whether British institutions can unwind a single-vendor US surveillance deal on process grounds.
That question now stretches well beyond London. The technology secretary, Liz Kendall, confirmed the government is conducting a full review of Palantir's £330m NHS contract, assessing whether to extend the deal or activate a break clause that would allow it to stop using the company's services in early 2027. The Science, Innovation and Technology Committee last week urged the government to trigger that break, calling Palantir's presence "an unacceptable point of weakness" in a public sector increasingly reliant on a handful of US tech firms. The Met block, the NHS review, and the threatened litigation together form a single argument about who decides what the British state buys, and from whom.
Khan's stated reason for blocking the Met contract was procedural. The procurement process had narrowed to a single supplier without, in his view, proper justification, and the wider strategy for buying AI had not been put to public scrutiny. "Only contender" was Khan's framing of the situation, not an independent finding. The Guardian's report cites the Times as the source for the pre-action letter itself; neither the letter's full text nor a court filing number has entered the public record, so the dispute is currently an intent to litigate, not a live claim.
Palantir's commercial and political profile makes the contest unusually charged. The company built its reputation on data analytics for Western intelligence and military customers, and its chief executive used an April post on X to sketch a political worldview that has put Palantir in the middle of US culture-war fights. That posture helps explain why the UK public-sector footprint has become politically combustible, but it is not the legal basis for either the Met block or the NHS review. Both turn on procurement process, not on the company's politics.
The question the litigation will press is whether procurement law, as Khan and the committee want to wield it, has enough teeth to break a single-vendor dependency once it has been established. Pre-action letters routinely settle, narrow, or escalate; they do not yet predict who wins. But the strategic stakes are clear. If the Met block holds, it gives UK mayors, police and crime commissioners, and departmental buyers a working template for unwinding or refusing deals with dominant US vendors. If Palantir persuades a court that the process Khan attacked was lawful, that template collapses, and the NHS review faces a harder political path.
The next concrete signals to watch are the substance of Palantir's grounds of challenge, the response from MOPAC, and whether the Department of Health and Social Care publishes a timetable for the NHS review. Each will narrow, or widen, the room British institutions have to say no.